Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 1535 versus Symbicort versus formoterol in severe COPD
2006-002489-20Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate + formoterol, budesonide and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Number of COPD exacerbations and Change in pre-dose morning FEV1 from baseline to 48 weeks. Started Sep 2006; status: completed.
02
Drugs
beclometasone dipropionate + formoterolbudesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-002489-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002489-20.